Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).
Journal: Journal of the National Cancer Institute
Published: February 06, 2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2026
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 11, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 25, 2025
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Journal: Journal of the National Cancer Institute
Published: August 22, 2024
Reply to G.B. Mann et al and S. Sorscher.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 15, 2024
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2023
Investigating potential disparities in clinical trial eligibility and enrollment at an NCI-designated comprehensive cancer center.
Journal: Cancer medicine
Published: September 20, 2022
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: December 16, 2021
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 30, 2021
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Journal: Breast cancer research and treatment
Published: May 14, 2021
Last Updated: 09/26/2026